Parkinson’s disease is a disability of the brain that is characterized with the loss of balance, slowness of movement, alongwith shaking and stiffness in the later stages. This condition usually develops after the age of 50 and is one of the most common nervous system disorders that the elderly suffer from.
Incessant research on the treatment of Parkinson’s disease resulted in the introduction of the carbidopa or levodopa (Sinemet®) that had initially revolutionized the treatment of the Parkinson’s disease, after which 15 more drugs were introduced which treated the genetic condition by adjusting the level of dopamine in the brain by stimulating the unresponsive receptors of the brain. These drugs have improved medical care for the patients suffering from this degenerative disorder and have allowed the doctors to customize treatment solutions that maximize benefits and reduce the adverse reactions. With major drugs like Azilect, Stalevo and Comtan that are employed to treat this disease, losing their patents by 2019, the approval and introduction of late-stage pipeline drugs is expected to see a substantial increase. Inspite of this speculated increase, the market impact of emerging therapies will be severely affected by generic competition.
The three emerging therapies
As per the Parkinson’s research news, all the emerging therapies will have a moderate impact on the market growth. The industry analysts do not expect any kind of major shifts in the treatment paradigm of Parkinson’s disease in the coming decade. Furthermore, generic competition will further suppress the market growth and this means that the future therapies will need to clearly demonstrate superiority over the present therapies to gain a competitive edge in this mature market.
Unmet needs in the therapies
Despite these challenges, there is an urgent need of disease modifying treatment solutions for Parkinson’s disease treatment methods. The currently available late stage PD therapy concentrates on the symptomatic agents that targets only niche populations and these products are restricted by its commercial potential. One of the greatest needs in the treatment of this disease today, is agents that will delay its progression – something that is still far from realization.
In the coming years, the generalization of Parkinson’s disease drugs will create a fragmented market with no clear market leader as such. Healthcare analysts expect that there will be a large number of similarly priced drugs that will be competing for the same market share. Thus to gain a competitive advantage in this pharmaceutical market segment, future therapies need to differentiate themselves from other treatment options and establish market supremacy.
For further insights,
About Research on Global Markets
Research on Global Markets is a leading source for market research on various sectors globally, offering premium research content from worldwide publishers of market research reports. Our database hosts premium market research content developed by global publishers. It offers premium industry research reports, company profiles and country briefs. We have a dedicated team of research professionals who can facilitate, in an unbiased manner, the process of identifying appropriate market research reports that are targeted to fulfill all your information-related requirements.
For more details on the content of each report and ordering information please contact:
US: +1 800 986 6819
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets.comBlog: blog.researchonglobalmarkets.com